Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

Publication date: Sep 09, 2019

Alemtuzumab is a highly effective therapy in relapse remitting multiple sclerosis (RRMS). The aim of this study is to elucidate the mechanism of action of the neuroprotective potential of alemtuzumab in RRMS. Therefore, the investigators will semi-annually analyse blood samples of RRMS patients treated with alemtuzumab up to 36 months. Using in vitro/ ex vivo assays the investigators aim to detect and characterize immune cells including their functional activity. Furthermore, the study aims to combine this analysis with clinical data (MRI, EDSS: Expanded Disability Status Scale, MSFC: Multiple Sclerosis Functional Composite) to reveal the underlining mechanism of action of alemtuzumab to further improve its efficacy and safety for present and future patients.

Concepts Keywords
Alemtuzumab MRI
Autoimmune Cladribine
Blood Biology
Cognitive Medicine
Connective Tissue Informed consent
Contraindication Medical specialties
Cranial MRI Autoimmune diseases
Cytopenias Multiple sclerosis
Disability CD52
Gadolinium Sanofi
Hemorrhage Alemtuzumab
Inflammatory Bowel Disease MS
Informed Consent Peptic ulcer
MRI Trauma illness
Muenster
Multiple Sclerosis
Neuroprotective
Patient Safety
Peptic Ulcer
Progressive
Psoriasis
Relapse
Rheumatoid Arthritis
Systemic Illness
Systemic Lupus Erythematosus
Trauma
Vasculitis
Vivo
White Matter

Semantics

Type Source Name
drug DRUGBANK Gadolinium
disease DOID psoriasis
disease MESH psoriasis
disease DOID inflammatory bowel disease
disease MESH inflammatory bowel disease
disease DOID vasculitis
disease MESH vasculitis
disease MESH vasculitis
pathway BSID Systemic lupus erythematosus
disease DOID systemic lupus erythematosus
disease MESH rheumatoid arthritis
disease DOID rheumatoid arthritis
pathway BSID Rheumatoid arthritis
disease MESH systemic lupus erythematosus
disease DOID autoimmune disease
disease MESH autoimmune disease
disease MESH hemorrhage
disease DOID peptic ulcer disease
disease MESH contraindication
gene UNIPROT RENBP
disease MESH Diagnosis
gene UNIPROT CYREN
gene UNIPROT DNMT1
gene UNIPROT CD69
disease DOID RRMS
disease DOID multiple sclerosis
disease MESH multiple sclerosis
disease MESH relapse
drug DRUGBANK Alemtuzumab
gene UNIPROT CD52

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *